论文信息 - Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial - 字舞流文

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

V. Gopalakrishnan | V. Anagnostou | Y. Zheng | D. Spigel | R. García-Campelo | A. Spira | T. Cascone | D. Daniel | I. Grenga | Rakesh Kumar | Y. Soo-Hoo | Lin-Yang Cheng | P. Forde | Lara McGrath | Edwin H Yau | R. Mager | Gozde Kar | Michael Surace | Jonathan D Spicer | J. Mazières | Bret R Sellman | Júlio Oliveira | Walter Weder | Maen Hussein | Oday Hamid | Jorge Blando | Tze Heng Tan | Jaime Rodriguez-Canales